About Ensho Therapeutics
Ensho Therapeutics is a private company based in Woodcliff Lake, New Jersey, incorporated in 2024 in Delaware. It has reported $35,181,948 raised in five offerings on Form D since August 2024. Its chief executive is Gerhard Hagn.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | Oct 15, 2026 | $7,281,948of $15.6M target | 7 | $1.0M | Equity, Securities on exerciseRule 506(b) | Form D ↗ |
| Jan 20, 2026 | Feb 9, 2026 | $0of $20.0M target | 9 | $0 | Equity, Securities on exerciseRule 506(b) | Form D ↗ |
| Jun 12, 2025 | Sep 12, 2025 | $22,500,000fully sold | 2 | $11.2M | DebtRule 506(b) | Form D ↗ |
| Oct 24, 2024 | Nov 12, 2024 | $5,000,000of $12.5M target | 1 | $5.0M | EquityRule 506(b) | Form D ↗ |
| Jul 19, 2024 | Aug 6, 2024 | $400,000of $2.0M target | 2 | $200K | Options, Securities on exercise, simple agreement for future equity.Rule 506(b) | Form D ↗ |
| Total, five offerings | $35,181,948 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Ensho Therapeutics's Form D filed Oct 15, 2026.
Earlier filings also listed Matthew McKevitt (executive officer, last listed Sep 2025), James Whitney (executive officer, last listed Sep 2025), Emily Weng (executive officer, last listed Sep 2025) and Bittoo Kanwar (executive officer, last listed Sep 2025).